Vicuron Pharmaceuticals Inc.
Records under this name other than patents Vicuron Pharmaceuticals Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Vicuron Pharmaceuticals Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,900,175 | Methods of administering dalbavancin for treatment of bacterial infections Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,655,676 | Use of amide derivative of GE 2270 factor A3 for the treatment of acne Formerly held Term ended Term ended Oct 22, 2025 · From the USPTO record | Term ended | Term ended Oct 22, 2025 | From the USPTO record |
| US 7,317,001 | Use of Ramoplanin to Treat Diseases Associated with the Use of Antibiotics Formerly held Term ended Term ended Dec 21, 2024 · High confidence | Term ended | Term ended Dec 21, 2024 | High confidence |
| US 7,319,088 | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof Formerly held Term ended Term ended Sep 25, 2024 · From the USPTO record | Term ended | Term ended Sep 25, 2024 | From the USPTO record |
| US 7,307,057 | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof Formerly held Term ended Ended no later than Jul 12, 2024 · From the USPTO record | Term ended | Ended no later than Jul 12, 2024 | From the USPTO record |
| US 7,351,687 | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof Formerly held Term ended Ended no later than Jul 12, 2024 · From the USPTO record | Term ended | Ended no later than Jul 12, 2024 | From the USPTO record |
| US 8,143,212 | Dalbavancin compositions for treatment of bacterial infections Formerly held Term ended Term ended Jan 12, 2024 · From the USPTO record | Term ended | Term ended Jan 12, 2024 | From the USPTO record |
| US 7,115,564 | Stable pharmaceutical compositions of dalbavancin and methods of administration Formerly held Term ended Term ended Nov 14, 2023 · From the USPTO record | Term ended | Term ended Nov 14, 2023 | From the USPTO record |
| US 7,119,061 | Dalbavancin compositions for treatment of bacterial infections Formerly held Term ended Ended no later than Nov 14, 2023 · From the USPTO record | Term ended | Ended no later than Nov 14, 2023 | From the USPTO record |
| US 7,169,890 | Process for the production of ramoplanin-like amide derivatives Formerly held Term ended Term ended Sep 8, 2023 · From the USPTO record | Term ended | Term ended Sep 8, 2023 | From the USPTO record |